esophageal-squamous-cell-carcinoma

Documents about esophageal-squamous-cell-carcinoma

• Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma#4567Europe PMC
• Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma#226243ClinicalTrials.gov
• Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer#121336ClinicalTrials.gov
• SLND Versus Non-Dissection Following ESD for T1a Stage Esophageal Squamous Cell Carcinoma#800920ClinicalTrials.gov
• Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study#181749ClinicalTrials.gov
• Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer#804902ClinicalTrials.gov
• Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC#417562ClinicalTrials.gov
• Data-driven prognostic factors analysis and personalized follow-up strategies for post-progression survival in locally advanced esophageal squamous cell carcinoma after definitive chemoradiotherapy.#9740PubMed
• Development and validation of an interpretable Random Forest model for predicting recurrence after endoscopic submucosal dissection in superficial oesophageal squamous cell carcinoma.#9745PubMed
• Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma#889787ClinicalTrials.gov
• A Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma#848882ClinicalTrials.gov
• Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer.#854019ClinicalTrials.gov
• Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma#279517ClinicalTrials.gov
• Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma#967154ClinicalTrials.gov
• Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)#143546ClinicalTrials.gov
• The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer#146444ClinicalTrials.gov
• Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma#217028ClinicalTrials.gov
• Pre-Surgery If Needed for Oesophageal Cancer#865817ClinicalTrials.gov
• Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma#911433ClinicalTrials.gov
• Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer#146460ClinicalTrials.gov
• Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)#893419ClinicalTrials.gov
• Intratumor#289158PubMed
• Role of Esophagectomy in Complete Responders to CCRT#812609ClinicalTrials.gov
• Trial of Docetaxel, Cisplatin, Fluorouracil (5-FU) for Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC)#888221ClinicalTrials.gov
• Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma#981417ClinicalTrials.gov
• Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer#860239ClinicalTrials.gov
• RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: AN OBSERVATIONAL STUDY#903530ClinicalTrials.gov
• Fursultiamine in Esophageal Squamous Cell Carcinoma Patients Who Receive Concurrent Chemoradiotherapy#981949ClinicalTrials.gov
• A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.#230394ClinicalTrials.gov
• DDR1 in esophageal squamous cell carcinoma: bioinformatics discovery and experimental validation.#368070NCBI PubMed Central
• Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC#848178ClinicalTrials.gov
• Low-Dose Radiotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Resistant to First-Line Chemotherapy Combined With Immunotherapy#249619ClinicalTrials.gov
• Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma#349941ClinicalTrials.gov
• The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers#866328ClinicalTrials.gov
• First-Line PD-1 Inhibitor-Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta-Analysis of Phase III Trials#991168Bielefeld Pub
• Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.#912493ClinicalTrials.gov
• Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma#463707ClinicalTrials.gov
• Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC#307464ClinicalTrials.gov
• Sintilimab Plus NCT or NCRT Versus NCRT for ESCC#417547ClinicalTrials.gov
• Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC#825565ClinicalTrials.gov
• Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection#311124ClinicalTrials.gov
• Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma#907672ClinicalTrials.gov
• Immunotherapy After Radiotherapy in Elderly ESCC#127597ClinicalTrials.gov
• Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor#180395ClinicalTrials.gov
• Proteome profiles of esophageal squamous cell carcinoma tie mitochondrial complex I to immunotherapy.#193428NCBI PubMed Central
• a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC Study#343819ClinicalTrials.gov
• Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）#387168ClinicalTrials.gov
• Circular RNAs in esophageal squamous cell carcinoma: What do we know so far?#399660NCBI PubMed Central
• Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.#981186ClinicalTrials.gov
• A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)#909537ClinicalTrials.gov